Last reviewed · How we verify
Habekacin (ARBEKACIN)
Habekacin (generic name: ARBEKACIN) is a arbekacin drug. It is currently in Phase 2 development.
Arbekacin works by inhibiting protein synthesis in bacteria, preventing them from producing essential proteins and ultimately leading to cell death.
Arbekacin, also known as Habekacin, is a small molecule antibiotic in the arbekacin class. It is used to treat bacterial infections, although its specific target and approved indications are unknown. The commercial status of arbekacin is unclear, and it may be patented or available as a generic medication. Key safety considerations include its low bioavailability and short half-life of 2.46 hours. Further research is needed to fully understand the pharmacology and clinical use of arbekacin.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ARBEKACIN |
|---|---|
| Drug class | arbekacin |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells are like factories that make proteins to keep you healthy. Bacteria are like tiny factories that make proteins to harm you. Arbekacin stops these bacterial factories from working by blocking the production of essential proteins, which ultimately kills the bacteria.
Approved indications
Common side effects
Key clinical trials
- Arbekacin Treatment of Adult Patients With Infections Caused by Multidrug-resistant Bacteria
- A Study to Assess the Pharmacokinetic Profile, the Safety, and the Tolerability of ME1100 Inhalation Solution in Patients With Mechanically Ventilated Bacterial Pneumonia (PHASE1)
- Phase II Study of NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular Dystrophy (PHASE2)
- Pharmacokinetics and Safety Study of ME1100 in Healthy Volunteers (PHASE1)
- Intrapulmonary Pharmacokinetics of ME1100 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Habekacin CI brief — competitive landscape report
- Habekacin updates RSS · CI watch RSS
Frequently asked questions about Habekacin
What is Habekacin?
How does Habekacin work?
What is the generic name of Habekacin?
What drug class is Habekacin in?
What development phase is Habekacin in?
Related
- Drug class: All arbekacin drugs
- Therapeutic area: All drugs in Infectious Disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing